Suppr超能文献

广泛耐药肺炎克雷伯菌抵消了头孢他啶-阿维巴坦耐药获得伴随的适应性和毒力代价。

Extensively Drug-Resistant Klebsiella pneumoniae Counteracts Fitness and Virulence Costs That Accompanied Ceftazidime-Avibactam Resistance Acquisition.

机构信息

Pharmaceutical Microbiology, Institute of Pharmacy, University of Greifswaldgrid.5603.0, Greifswald, Germany.

Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswaldgrid.5603.0, Greifswald, Germany.

出版信息

Microbiol Spectr. 2022 Jun 29;10(3):e0014822. doi: 10.1128/spectrum.00148-22. Epub 2022 Apr 18.

Abstract

The ability of extensively drug-resistant (XDR) Klebsiella pneumoniae to rapidly acquire resistance to novel antibiotics is a global concern. Moreover, Klebsiella clonal lineages that successfully combine resistance and hypervirulence have increasingly occurred during the last years. However, the underlying mechanisms of counteracting fitness costs that accompany antibiotic resistance acquisition remain largely unexplored. Here, we investigated whether and how an XDR sequence type (ST)307 K. pneumoniae strain developed resistance against the novel drug combination ceftazidime-avibactam (CAZ-AVI) using experimental evolution. In addition, we performed and assays, molecular modeling, and bioinformatics to identify resistance-conferring processes and explore the resulting decrease in fitness and virulence. The subsequent amelioration of the initial costs was also addressed. We demonstrate that distinct mutations of the major nonselective porin OmpK36 caused CAZ-AVI resistance that persists even upon following a second experimental evolution without antibiotic selection pressure and that the Klebsiella strain compensates the resulting fitness and virulence costs. Furthermore, the genomic and transcriptomic analyses suggest the envelope stress response regulator and associated RpoE-regulated genes as drivers of this compensation. This study verifies the crucial role of OmpK36 in CAZ-AVI resistance and shows the rapid adaptation of a bacterial pathogen to compensate fitness- and virulence-associated resistance costs, which possibly contributes to the emergence of successful clonal lineages. Extensively drug-resistant Klebsiella pneumoniae causing major outbreaks and severe infections has become a significant challenge for health care systems worldwide. Rapid resistance development against last-resort therapeutics like ceftazidime-avibactam is a significant driver for the accelerated emergence of such pathogens. Therefore, it is crucial to understand what exactly mediates rapid resistance acquisition and how bacterial pathogens counteract accompanying fitness and virulence costs. By combining bioinformatics with and phenotypic approaches, this study revealed the critical role of mutations in a particular porin channel in ceftazidime-avibactam resistance development and a major metabolic regulator for ameliorating fitness and virulence costs. These results highlight underlying mechanisms and contribute to the understanding of factors important for the emergence of successful bacterial pathogens.

摘要

广泛耐药(XDR)肺炎克雷伯菌迅速获得新型抗生素耐药性的能力是一个全球性的关注点。此外,近年来,具有耐药性和高致病性的肺炎克雷伯菌克隆谱系越来越多地出现。然而,伴随抗生素耐药性获得而来的适应性成本的潜在机制在很大程度上仍未得到探索。在这里,我们使用实验进化研究了一种 XDR 序列型(ST)307 型肺炎克雷伯菌对新型药物组合头孢他啶-阿维巴坦(CAZ-AVI)的耐药性是如何产生的。此外,我们还进行了 和 测定、分子建模和生物信息学分析,以确定耐药性产生的过程,并探讨由此导致的适应性和毒力下降。我们还解决了最初成本改善的问题。我们证明,主要非选择性孔蛋白 OmpK36 的不同突变导致 CAZ-AVI 耐药性,即使在没有抗生素选择压力的情况下进行第二次实验进化后,这种耐药性仍然存在,而这种肺炎克雷伯菌菌株补偿了由此产生的适应性和毒力成本。此外,基因组和转录组分析表明,包膜应激反应调节剂 和相关的 RpoE 调控基因是这种补偿的驱动因素。这项研究验证了 OmpK36 在 CAZ-AVI 耐药性中的关键作用,并表明了细菌病原体快速适应补偿与适应性和毒力相关的耐药性成本,这可能有助于成功克隆谱系的出现。 引起重大暴发和严重感染的广泛耐药肺炎克雷伯菌已成为全球医疗保健系统的重大挑战。对最后一线治疗药物(如头孢他啶-阿维巴坦)的快速耐药发展是此类病原体加速出现的重要驱动因素。因此,了解究竟是什么介导了快速耐药性的获得以及细菌病原体如何对抗伴随的适应性和毒力成本至关重要。通过将生物信息学与 和 表型方法相结合,本研究揭示了特定孔蛋白通道突变在头孢他啶-阿维巴坦耐药性发展中的关键作用,以及一种主要代谢调节剂在改善适应性和毒力成本方面的作用。这些结果强调了潜在的机制,并有助于理解对成功细菌病原体出现的重要因素。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3c0c/9241641/cb7c6cf549e2/spectrum.00148-22-f001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验